Detalhe da pesquisa
1.
FDA review summary of patient-reported outcome results for ibrutinib in the treatment of chronic graft versus host disease.
Qual Life Res;
29(7): 1903-1911, 2020 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32100182
2.
FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the BRAFV600 Mutation.
Oncologist;
23(12): 1520-1524, 2018 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30120160
3.
U.S. Food and Drug Administration approval summary: Eltrombopag for the treatment of pediatric patients with chronic immune (idiopathic) thrombocytopenia.
Pediatr Blood Cancer;
64(12)2017 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28627134
4.
Pain palliation measurement in cancer clinical trials: the US Food and Drug Administration perspective.
Cancer;
120(5): 761-7, 2014 Mar 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24375398
5.
U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia.
Oncologist;
19(1): 94-9, 2014 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24309980
6.
Commentary on Heath et al.
Clin Trials;
14(6): 572-574, 2017 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28764558
7.
FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma.
Oncologist;
15(4): 428-35, 2010.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20332142
8.
Older adults in hematologic malignancy trials: Representation, barriers to participation and strategies for addressing underrepresentation.
Blood Rev;
43: 100670, 2020 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32241586
9.
Development of a harmonized patient-reported outcome questionnaire to assess myelofibrosis symptoms in clinical trials.
Leuk Res;
59: 26-31, 2017 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28544906
10.
Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms.
Clin Cancer Res;
22(7): 1553-8, 2016 Apr 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26758559
11.
FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma.
Clin Cancer Res;
21(12): 2666-70, 2015 Jun 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25802282
12.
Clinical applications of genetics in sporadic cancers.
Semin Oncol Nurs;
20(3): 155-63, 2004 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-15491025
13.
U.S. Food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia.
Clin Cancer Res;
20(15): 3902-7, 2014 Aug 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24824310
14.
Reducing the toxicity of cancer therapy: recognizing needs, taking action.
Nat Rev Clin Oncol;
9(8): 471-8, 2012 07 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22751283
15.
U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.
Clin Cancer Res;
18(21): 5845-9, 2012 Nov 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22962441
16.
Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials-Response.
Clin Cancer Res;
22(22): 5618, 2016 11 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28151715
17.
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
J Clin Oncol;
26(22): 3709-14, 2008 Aug 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-18669456
18.
A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling.
Cancer;
110(2): 309-17, 2007 Jul 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17559139
19.
A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer.
Cancer;
109(7): 1323-30, 2007 Apr 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17330838